[go: up one dir, main page]

NO20070199L - Substituerte kinazoloner som anti-kreftmidler - Google Patents

Substituerte kinazoloner som anti-kreftmidler

Info

Publication number
NO20070199L
NO20070199L NO20070199A NO20070199A NO20070199L NO 20070199 L NO20070199 L NO 20070199L NO 20070199 A NO20070199 A NO 20070199A NO 20070199 A NO20070199 A NO 20070199A NO 20070199 L NO20070199 L NO 20070199L
Authority
NO
Norway
Prior art keywords
cancer agents
chemical compounds
relates
useful
quinazolones
Prior art date
Application number
NO20070199A
Other languages
English (en)
Inventor
Jayachandran Ezhuthachan
Paul Dermot Lyne
Brian Aquila
Timothy Pontz
John W Lee
Les Dakin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070199L publication Critical patent/NO20070199L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår kjemiske forbindelser med formel (I): eller farmasøytisk akseptable salter derav, som har B-Raf-hemmende aktivitet og følgelig er anvendelige på grunn av sin anti-kreft-aktivitet og således ved metoder for behandling av menneske- eller dyrekroppen. Oppfinnelsen angår også fremgangsmåter for fremstilling av nevnte kjemiske forbindelser, farmasøytiske preparater inneholdende dem, og anvendelse av dem ved fremstilling av medikamenter anvendelig til å frembringe en anti-kreft-effekt hos et varmblodig dyr, så som mennesker.
NO20070199A 2004-06-15 2007-01-11 Substituerte kinazoloner som anti-kreftmidler NO20070199L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57926504P 2004-06-15 2004-06-15
PCT/GB2005/002327 WO2005123696A1 (en) 2004-06-15 2005-06-14 Substituted quinazolones as anti-cancer agents

Publications (1)

Publication Number Publication Date
NO20070199L true NO20070199L (no) 2007-01-11

Family

ID=34970483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070199A NO20070199L (no) 2004-06-15 2007-01-11 Substituerte kinazoloner som anti-kreftmidler

Country Status (13)

Country Link
US (1) US20080275022A1 (no)
EP (1) EP1761506A1 (no)
JP (1) JP2008502666A (no)
KR (1) KR20070028536A (no)
CN (1) CN101001845A (no)
AU (1) AU2005254771A1 (no)
BR (1) BRPI0512075A (no)
CA (1) CA2568756A1 (no)
IL (1) IL179580A0 (no)
MX (1) MXPA06014696A (no)
NO (1) NO20070199L (no)
WO (1) WO2005123696A1 (no)
ZA (1) ZA200610302B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1966159A2 (en) * 2005-12-22 2008-09-10 AstraZeneca AB Chemical compounds
CN101421253A (zh) * 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7879846B2 (en) 2006-09-21 2011-02-01 Kyorin Pharmaceutical Co.., Ltd. Serine hydrolase inhibitors
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
KR100871128B1 (ko) * 2007-04-17 2008-12-03 한국생명공학연구원 4-헥사데카노일-1,1-디메틸-피페라진-1-윰 아이오다이드를포함하는 항암제
EP2200999B1 (en) * 2007-09-26 2014-08-13 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
JP6125663B2 (ja) 2012-12-21 2017-05-10 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
HK1223911A1 (zh) 2013-06-14 2017-08-11 Gilead Sciences, Inc. 磷脂醯肌醇3-激酶抑制剂
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN107074828B (zh) * 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
US10377770B2 (en) 2015-12-18 2019-08-13 Novartis Ag Tricyclic compounds and compositions as kinase inhibitors
KR101789430B1 (ko) 2016-06-28 2017-10-25 동국대학교 산학협력단 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN113603707B (zh) * 2016-12-12 2023-03-31 石药集团中奇制药技术（石家庄）有限公司 一类含有三环杂芳基的化合物
WO2019063704A1 (en) * 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
WO2019063708A1 (en) * 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
KR102041376B1 (ko) * 2018-04-10 2019-11-06 고려대학교 산학협력단 1-(4-(3-클로로-4(3-플루오로벤질옥시)페닐아미노)퀴나졸린-6-일)유레아를 포함하는 대장암 예방 또는 치료용 조성물
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110327344A (zh) * 2019-06-12 2019-10-15 徐州医科大学 喹唑啉酮类化合物在制备与肿瘤有关药物方面的应用
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2025540768A (ja) * 2022-11-30 2025-12-16 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 新規抗がん治療としての３－フェニルキノアゾリノン類
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200804B1 (pl) * 1999-03-17 2009-02-27 Astrazeneca Ab Pochodne amidowe, sposoby ich wytwarzania, ich kompozycje farmaceutyczne oraz ich zastosowanie
AU4556800A (en) * 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
AU2002249275A1 (en) * 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf

Also Published As

Publication number Publication date
JP2008502666A (ja) 2008-01-31
EP1761506A1 (en) 2007-03-14
AU2005254771A1 (en) 2005-12-29
US20080275022A1 (en) 2008-11-06
IL179580A0 (en) 2007-05-15
BRPI0512075A (pt) 2008-02-06
CA2568756A1 (en) 2005-12-29
ZA200610302B (en) 2008-10-29
KR20070028536A (ko) 2007-03-12
CN101001845A (zh) 2007-07-18
MXPA06014696A (es) 2007-02-12
WO2005123696A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20073719L (no) Kjemiske forbindelser
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20082709L (no) Kjemiske forbindelser
NO20091683L (no) Kjemiske forbindelser
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
TW200635899A (en) Chemical compounds
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20091703L (no) Heterocykliske sylfonamider med EDG-I antagonistisk aktivitet
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20061743L (no) Kinazolinderivater
TW200736234A (en) Chemical compounds
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
NO20092342L (no) Azaspiroderivativater
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
TW200615266A (en) Organic compounds
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application